Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relaps
- PDF / 245,382 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 55 Downloads / 222 Views
ORIGINAL ARTICLE
Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma Ewa Lech-Maranda • Jacques Bienvenu • Florence Broussais-Guillaumot Anne-Sophie Michallet • Krzysztof Warzocha • Przemysław Bilin´ski • Peter Boyle • Bertrand Coiffier • Gilles Salles
•
Received: 15 July 2012 / Accepted: 20 December 2012 / Published online: 3 January 2013 Ó L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2012
Abstract The aim of this study was to verify whether pretreatment plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis and survival of patients with diffuse large B-cell lymphoma (DLBCL). Plasma VEGF levels were assessed at the time of diagnosis in 157 DLBCL patients treated with anthracycline-based chemotherapy. Plasma VEGF levels greater than or equal to the highest quartile (high VEGF levels) were associated with lower probability of a complete remission achievement (odds ratio 0.3; 95 % confidence interval [CI]: 0.1–0.6; p = 0.002) in univariate as well as in multivariate E. Lech-Maranda J. Bienvenu B. Coiffier G. Salles Equipe d’Accueil ‘‘Pathologie des Cellules Lymphoı¨des’’, Universite´ Claude Bernard, Lyon, France
analysis (p = 0.04). The estimated 3-year progression-free survival (PFS) rate of patients with high VEGF levels was 31.7 % (95 % CI 17–51) compared to the 62.5 % 3-year PFS rate (95 % CI 53–71; p = 0.0004) in the patients with lower values. The former group of patients demonstrated an estimated 3-year overall survival (OS) rate of 47.1 % (95 % CI 30–65) in contrast to the 3-year OS rate of 64.3 % (95 % CI 54–73; p = 0.02) in the latter. In multivariate analysis, the high VEGF level retained its independent impact on shorter PFS (p = 0.02). Our results suggest that VEGF plays an important role in the clinical course of DLBCL. VEGF may be a useful marker for selecting the patients for whom new treatment approaches, especially those based on VEGF inhibitors, could be recommended.
E. Lech-Maranda (&) K. Warzocha P. Bilin´ski Department of Hematology, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14, 02-776 Warsaw, Poland e-mail: [email protected]
Keywords Vascular endothelial growth factor Diffuse large B-cell lymphoma Chemotherapy Prognosis
E. Lech-Maranda Department of Hematology, Medical University of Lodz, Lodz, Poland
Introduction
J. Bienvenu Laboratoire d’Immunologie, Centre Hospitalier Lyon-Sud, Pierre-Be´nite, France F. Broussais-Guillaumot A.-S. Michallet B. Coiffier G. Salles Hospices Civils de Lyon, Service d’He´matologie, Centre Hospitalier Lyon-Sud, Pierre-Be´nite, France P. Bilin´ski Chief Sanitary Inspectorate, Warsaw, Poland P. Boyle International Prevention Research Institute, Lyon, France
The importance of angiogenesis for malignant tumor growth and the development of metastatic lesions have been reported in a variety of solid tumors as well as in hematolo
Data Loading...
